In this regard, we hypothesized that the dual inhibition of DNMT1 and G9a could reactivate hypermethylated and silenced genes of MSCs from MM patients preserving their osteogenic potential and therefore preventing myeloma-associated bone loss. The gene discussed is EHMT2; the disease is Miyoshi myopathy.